Ahmad Tarhini, MD, PhD, director, Cutaneous Clinical and Translational Research, leader, Neoadjuvant and Adjuvant Translational Science Program, senior member, Moffitt Cancer Center, Research Institute Departments of Cutaneous Oncology and Immunology; professor, Oncologic Sciences, University of South Florida Morsani College of Medicine; chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN); chair, ORIEN ImmunoOncology Research Subcommittee, discusses the use of high-dose bolus interleukin-2 (IL-2) with concurrent low-dose ipilimumab (Yervoy), followed sequentially by nivolumab (Opdivo), in patients with advanced melanoma.
2024
15-year-old Virginia scientist created a soap that could treat skin cancer, named Time’s 2024 Kid of the Year
Time magazine and Time for Kids has chosen its 2024 Kid of the Year — and it’s Heman Bekele, a teenager who could change the way skin cancer is treated.
Innovative Melanoma Treatment Among NCInnovation’s $5.2 Million Research Funding Recipients
Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson’s research in patients with advanced melanoma.
Giant Melanocytic Nevi Portend More Aggressive Melanomas in Younger Patients
Melanomas that develop from giant pigmented nevi are diagnosed in younger patients more commonly than other melanomas; and while more these are more aggressive in patients younger than 10 years of age, they are mostly localized at the time of diagnosis, according to study results published in the Journal of the American Academy of Dermatology.